leadf
logo-loader
viewMindset Pharma Inc
(
CSE:MSETOTCQB:MSSTFFRA:9DF
)

Mindset Pharma develops rodent studies to differentiate between psychedelic and non-psychedelics

Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF, FRA:9DF) (CSE:MSET, OTCQB:MSSTF, FRA:9DF) CEO James Lanthier and Chief Scientific Officer Joseph Araujo joined Proactive to explain how the company has been able confirm the psychedelic effect of its novel compounds with greater accuracy.

Lanthier and Araujo say in partnership with InterVivo Solutions, Mindset has trained rats to discriminate psilocybin effects from saline via oral and subcutaneous dosing, which to the company’s knowledge is a first in the psychedelics field of research.

Quick facts: Mindset Pharma Inc

Follow
CSE:MSET

Price: 0.76 CAD

Market Cap: $54.88 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Mindset Pharma say latest results further validate lead candidate's...

Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF, FRA:9DF) (CSE:MSET) (OTCQB:MSSTF) (FRA:9DF) CEO James Lanthier and Chief Scientific Officer Joseph Araujo tell Proactive that its lead candidate MSP-1014 was comparable to psilocybin assessed using a drug discrimination assay. Araujo and Lanthier...

1 week, 5 days ago

2 min read